Ellevest Inc’s Adamas Pharmaceuticals ADMS Stock Holding History

Ellevest Inc’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-127	Closed	-$1K	–	1422
2020 Q3	$1K	Hold	127	–	–	﹤0.01%	1100
2020 Q2	$0	Buy	+127	New	+$373	﹤0.01%	1428

Other funds holding ADMS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Ellevest Inc's ADMS Position: Q4 2020 in Review

Ellevest Inc sold out of Adamas Pharmaceuticals (ADMS) in Q4 2020, closing a stake of 127 shares — an estimated $1K sold.

Ellevest Inc first reported a position in ADMS in Q2 2020 and held it in 2 quarters. The position peaked at $1K in Q3 2020. 65 funds tracked by Wall St. Rank hold ADMS as of Q4 2020.

Ellevest Inc reported no remaining Adamas Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Ellevest Inc sold 127 Adamas Pharmaceuticals shares in Q4 2020, an estimated $1K.
Ellevest Inc first reported a position in Adamas Pharmaceuticals in Q2 2020 and held it in 2 quarters.
Ellevest Inc's Adamas Pharmaceuticals position peaked at $1K in Q3 2020.
65 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2020.

Based on Ellevest Inc's 13F filing for Q4 2020, filed 4 Feb 2021.